lung cancer

The coverage decision limits the test mainly to patients with advanced lung cancers who haven't been genomically profiled and who can't receive tissue testing.

The company is confident about bringing the test to market despite potential future competition and views it as an easy fit for its existing sales channels.

The deal gives Biodesix an additional test in the lung cancer space, Indi's XL2, which helps to classify lung nodules identified by imaging scans as benign or malignant.

As the firm continues to move toward commercialization of its test, its loss dropped to $3.8 million, or $.12 per share, from $4.7 million, $.16 per share, in the same period last year.

Presentations largely reflected negatively on the utility of PD-L1 for stratifying response, but pivotal new data on tumor mutational burden as assessed by Foundation Medicine's genomic sequencing panel.

The lawsuits allege the company made false and/or misleading statement and/or failed to disclose information that was pertinent to investors.

The firm is in the midst of evaluating its strategic options and has hired Raymond James to assist in the process, which could include the sale of the firm, it said.

The company's net loss climbed about 30 percent to $4.0 million for Q4 2017, and reached $19.4 million for the full year.

The company has highlighted the study as evidence that its test would outperform Roche's FDA-approved liquid biopsy assay if implemented in the clinic.

The lab, which serves hospitals in India and surrounding countries, will use Precipio's ICE COLD-PCR technology to offer blood-based mutation tests.

Pages